• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于结构的新型糖原合酶激酶3抑制剂的从头设计

Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.

作者信息

Dessalew Nigus, Bharatam Prasad V

机构信息

Department of Pharmaceutical Chemistry, School of Pharmacy, Addis Ababa University, PO Box 1176, Addis Ababa, Ethiopia.

出版信息

Bioorg Med Chem. 2007 Jun 1;15(11):3728-36. doi: 10.1016/j.bmc.2007.03.048. Epub 2007 Mar 18.

DOI:10.1016/j.bmc.2007.03.048
PMID:17399989
Abstract

Glycogen synthase kinase 3 (GSK-3) is a serine/threonine kinase that has captured great attention in drug discovery projects. Structure based design has been successfully carried out to find a novel class of GSK-3 inhibitors using the Ludi de novo ligand design program. A total of 15 potential leads are suggested from the study. The structures have been validated through detailed analysis of the Ludi score values and by molecular docking experiment using FlexX. The hits have been further verified through: (1) visual examination of how well the hits dock into the GSK-3beta binding site; (2) comparative analysis of their FlexX, G_Score, PMF_Score, ChemScore, and D_scores values; (3) a comparative investigation of the docking scores of the hits with those of the reported inhibitors after calibration of the docking procedure with 17 previously reported inhibitors; (4) determination of the binding mode of the hits and comparison with that of the so far known inhibitors. Hits retaining interactions with the common amino acids of GSK-3beta binding site were taken to represent potential leads. Structurally the hits designed are mainly flat nitrogen heterocycles. These hits are expected to be important additions to the search of GSK-3 inhibitors and may provide invaluable insights to further understand the structural basis of catalysis and inhibition of this kinase.

摘要

糖原合酶激酶3(GSK-3)是一种丝氨酸/苏氨酸激酶,在药物研发项目中备受关注。基于结构的设计已成功开展,使用Ludi从头配体设计程序寻找新型GSK-3抑制剂。该研究共提出了15个潜在先导化合物。通过对Ludi评分值的详细分析以及使用FlexX进行分子对接实验,对这些结构进行了验证。命中的化合物已通过以下方式进一步验证:(1)直观检查命中化合物与GSK-3β结合位点的对接效果;(2)比较它们的FlexX、G_Score、PMF_Score、ChemScore和D_scores值;(3)在用17种先前报道的抑制剂对对接程序进行校准后,比较命中化合物与报道抑制剂的对接分数;(4)确定命中化合物的结合模式并与已知抑制剂的结合模式进行比较。保留与GSK-3β结合位点常见氨基酸相互作用的命中化合物被视为潜在先导化合物。从结构上看,设计的命中化合物主要是扁平的氮杂环。这些命中化合物有望成为寻找GSK-3抑制剂的重要补充,并可能为进一步理解该激酶的催化和抑制结构基础提供宝贵的见解。

相似文献

1
Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.基于结构的新型糖原合酶激酶3抑制剂的从头设计
Bioorg Med Chem. 2007 Jun 1;15(11):3728-36. doi: 10.1016/j.bmc.2007.03.048. Epub 2007 Mar 18.
2
Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening.基于结构的虚拟筛选鉴定潜在的糖原激酶-3抑制剂
Biophys Chem. 2007 Jul;128(2-3):165-75. doi: 10.1016/j.bpc.2007.04.001. Epub 2007 Apr 19.
3
Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.利用药效团映射和虚拟筛选研究潜在的糖原合酶激酶3抑制剂
Chem Biol Drug Des. 2006 Sep;68(3):154-65. doi: 10.1111/j.1747-0285.2006.00430.x.
4
Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.通过基于配体和结构的药物设计,鉴定新型先导化合物作为选择性和竞争性糖原合酶激酶-3β抑制剂并进行体外评估。
J Mol Graph Model. 2014 Sep;53:31-47. doi: 10.1016/j.jmgm.2014.06.013. Epub 2014 Jul 12.
5
A new protocol for predicting novel GSK-3β ATP competitive inhibitors.一种预测新型 GSK-3β ATP 竞争抑制剂的新方案。
J Chem Inf Model. 2011 Jun 27;51(6):1431-8. doi: 10.1021/ci2001154. Epub 2011 Jun 9.
6
Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.通过虚拟筛选鉴定苯并噻嗪酮新型支架作为非-ATP 竞争型糖原合酶激酶-3β抑制剂。
Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6. doi: 10.1016/j.bmcl.2012.09.043. Epub 2012 Sep 23.
7
Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.4-氨基-5,6-二芳基-呋喃并[2,3-d]嘧啶作为强效糖原合酶激酶-3抑制剂的合理设计
Bioorg Med Chem Lett. 2008 Mar 15;18(6):1967-71. doi: 10.1016/j.bmcl.2008.01.113. Epub 2008 Feb 2.
8
Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).苯并噻氮杂䓬酮(BTZs)作为糖原合酶激酶-3β(GSK-3β)新型非ATP竞争性抑制剂的设计、合成及生物学评价
Eur J Med Chem. 2013 Mar;61:95-103. doi: 10.1016/j.ejmech.2012.09.021. Epub 2012 Sep 21.
9
Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.新型糖原合成酶激酶-3β抑制剂 1-苯基吡唑并[3,4-e]吡咯并[3,4-g]吲唑啉-4,6(1H,5H)-二酮的设计、合成与生物评价。
J Med Chem. 2013 Dec 27;56(24):10066-78. doi: 10.1021/jm401466v. Epub 2013 Dec 11.
10
Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.奥氮平抑制糖原合酶激酶-3β:通过对接模拟和实验验证的研究
Eur J Pharmacol. 2008 Apr 14;584(1):185-91. doi: 10.1016/j.ejphar.2008.01.019. Epub 2008 Jan 30.

引用本文的文献

1
Tau as a therapeutic target for Alzheimer's disease.tau 作为阿尔茨海默病的治疗靶点。
Curr Alzheimer Res. 2011 Sep;8(6):666-77. doi: 10.2174/156720511796717195.
2
Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking.3-苯胺基-4-苯基马来酰亚胺对糖原合酶激酶-3的抑制作用:来自三维定量构效关系和对接的见解
J Comput Aided Mol Des. 2009 Feb;23(2):113-27. doi: 10.1007/s10822-008-9244-1. Epub 2008 Oct 7.